Framycetin is an aminoglycoside antibiotic and it also inhibits hammerhead ribozyme (Ki: 13.5 μM).

Neomycin B targets the bacterial and human ribosomes and affects translation. Neomycin B is used clinically to treat hepatic encephalopathy (by reducing ammonium levels in the gut) and enteropathogenic Escherichia coli infections. The addition of neomycin B, to an HCC cell line, selectively inhibits the production of the mature miRNA, boosts a downstream protein, and inhibits invasion [2]. The aminoglycoside antibiotic neomycin B causes misreading of the genetic code during translation and inhibits several ribozymes. The ribosomal target site of neomycin B is the 16 S rRNA 1400 to 1500 region, which has been clearly demonstrated by dissecting this domain from a small RNA of 27 nucleotides. This small subdomain of the 16 S rRNA is protected from chemical modification by neomycin at the same positions as in the context of the 30 S subunit [4]. Neomycin B interacts with various target RNAs that have no primary sequence homology. This means that the drug binds to a structural rather than a sequence motif of the RNA. Its primary cognate target is the decoding site of the 16S rRNA, but it also binds to the Rev-responsive element in HIV-1, a group I introns, and the hammerhead ribozyme, and thus inhibits their biological function [3].

119-04-0

C23H46N6O13

614.64

Fradiomycin B;新霉素B;Neomycin B;Framycetin

DMSO:50 mg/mL (81.35 mM),Need ultrasonic
H2O:100 mg/mL (162.70 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years